Back to the article

HealthRX.com · Printable question sheet

Switching report check sheet: weigh what you read, then ask the prescriber

Write down the switching story you read and sort it into an evidence tier before acting on it. Then take the questions to the prescriber who would manage the change, with the trial and real-world numbers that put the story in context.

Companion to “Zepbound Reviews: What Real Users Report When Switching To or From Tirzepatide” · healthrx.com/reviews-zepbound/switching-reports · Facts checked 2026-10-18

Where you are now

Current medicine, weekly dose and last injection date
How long on this dose
Why a switch is on your mindplateau, side effects, coverage, cost, other

The report you read

Where it came fromforum, review site, friend, article
What it claimed
Any number it gave, and where that number came from

Which tier is it?

  • Label or regulator statement: dosing, warnings, approved uses
  • Randomized trial: an average result in a defined group
  • Real-world cohort: typical patients, more confounding
  • Forum or review post: no denominator, strong selection bias

Numbers that put a report in context

  • In the head-to-head trial over 72 weeks, weight fell by a mean 20.2% with tirzepatide and 13.7% with semaglutide.[1]
  • In routine US care, people still on treatment at 12 months had lost a mean 15.3% on tirzepatide and 8.3% on semaglutide.[2]
  • In that cohort, 55.9% on tirzepatide and 52.5% on semaglutide stopped during follow-up.[2]
  • Zepbound's label starts every indication at 2.5 mg weekly for 4 weeks, then allows 2.5 mg steps after at least 4 weeks on a dose.[3]

Questions for the prescriber

  1. Would I start Zepbound at the lowest dose even after months on semaglutide?
  2. When should the first Zepbound injection fall relative to my last semaglutide dose?
  3. Does my plan cover the change, and does it need a new prior authorization?
  4. If I have type 2 diabetes, should insulin or a sulfonylurea change during the switch?
  5. What result after how long would make you suggest switching back?

Call promptly during a switch if

  • Belly pain is severe or will not settle, sometimes reaching the back.[3]
  • Vomiting or diarrhea keeps you from holding down fluids.[3]
  • You take insulin or a sulfonylurea and have signs of low blood sugar.[3]
Sources for the facts on this sheet
  1. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med 2025. PMID 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/
  2. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med 2024. PMID 38976257. https://pubmed.ncbi.nlm.nih.gov/38976257/
  3. Eli Lilly and Company, via DailyMed. Zepbound (tirzepatide) injection, for subcutaneous use: prescribing information and Medication Guide. Effective 2026-08-28. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.